The estimated Net Worth of Paul E Firuta is at least $584 Tausend dollars as of 3 January 2018. Paul Firuta owns over 5,864 units of uniQure N.V stock worth over $466,323 and over the last 8 years Paul sold QURE stock worth over $118,042.
Paul has made over 1 trades of the uniQure N.V stock since 2018, according to the Form 4 filled with the SEC. Most recently Paul sold 5,864 units of QURE stock worth $118,042 on 3 January 2018.
The largest trade Paul's ever made was selling 5,864 units of uniQure N.V stock on 3 January 2018 worth over $118,042. On average, Paul trades about 838 units every 0 days since 2017. As of 3 January 2018 Paul still owns at least 85,251 units of uniQure N.V stock.
You can see the complete history of Paul Firuta stock trades at the bottom of the page.
Paul's mailing address filed with the SEC is C/O ACHILLION PHARMACEUTICALS, INC., 1777 SENTRY PARKWAY W, BLDG 14, STE 200, BLUE BELL, PA, 19422.
Over the last 8 years, insiders at uniQure N.V have traded over $35,572,573 worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van, Paula Soteropoulos und William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of $37,634. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth $6,309.
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
uniQure N.V executives and other stock owners filed with the SEC include: